ArticleBMC complementary medicine and therapies2025
Prunus amygdalus var. amara seed extract enhances the antileishmanial activity of miltefosine.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLeishmaniasis, an infectious disease transmitted via sand flies is caused by the protozoan parasite of Leishmania spp. The treatment of this disease is quite challenging due to the high cost, resistance, and toxicity of conventional drugs. Various research studies have demonstrated that plant based drug possess least toxicity, anti-inflammatory and anti-oxidant properties. Here, evaluation of anti-leishmanial activity of methanolic Prunus amygdalus var. amara seed extract was conducted and found that it inhibited L. donovani proliferation and cause apoptosis. Moreover, its combinations with miltefosine enhanced antileishmanial effects. GC-MS analysis confirmed the presence of various phytochemicals in the extract that contributed pharmacological efficacy. These findings highlighted the potential of herbal products as a valuable source of new treatments for leishmaniasis.
methodsThe antileishmanial effect was determined by promastigote and amastigote assays. Parasite load was evaluated by staining L. donovani-infected macrophages with modified Giemsa stain. Cytotoxicity of seed extract was estimated by MTT (3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay. In addition, Pro-apoptotic events were inferred using RT-PCR and qRT-PCR. Further characterization of phytoconstituents was evaluated by gas chromatography and mass spectrometry.
resultsThe extract promoted a dose-dependent reduction in growth of promastigotes (IC50 = 43.12 ± 3.03 μg/ml) and amastigotes (IC50 = 49.65 ± 3.34 μg/ml). Further, extract in combination with miltefosine showed enhanced antileishmanial activity against both forms of the L. donovani, promastigotes (IC50 = 4.547 ± 1.2 μg/ml) as well as amastigotes (IC50 = 19.54 ± 2.4 μg/ml). Early-stage apoptotic events were also observed in promastigote forms by determining the increased expression of LdMetacaspase and PARP1. The cytotoxic potential on THP-1 differentiated macrophages was assessed and indicated insignificant cytotoxicity of different doses of the extract (CC50 = 799.19 ± 134.59 μg/ml) and in combination with miltefosine (CC50 = 384.16 ± 177.47 μg/ml). Furthermore, the presence of phytocompounds like chaulmoogric acid and hydnocarpic acid was described, for the first time, in Prunus amygdalus var. amara seed extract.
conclusionThe findings indicated that EPA plays a significant role in combating leishmaniasis and holds promise as a potential treatment for this disease. Moreover, when combined with miltefosine, EPA demonstrated increased effectiveness against leishmaniasis. Therefore, the combination of EPA and miltefosine presents a more promising outlook as a potential therapy for leishmaniasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.